Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 279
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
The Problems We Will Be Lucky to Have
Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date
Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It
Compass Says NDA Will Be Filed Within Two Weeks, Declines to Comment on Usona
Podcast: Usona Files Psilocybin Application, We Review 610 Comments Submitted to FDA, and FDA Approves NRx’s Generic Ketamine
MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston...
Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support
The Chopra Foundation and MindMed Enter Into Letter of Intent to...
Cybin Granted IRB Approval for Phase II Clinical Trials of its...
Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group
PT244 – Mark Haberstroh – Mushrooms, Retreat Centers, and Safety
Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update
More than 80% of Americans report one or more symptoms of...
The Impact of Specific Genes on Cannabis Use Disorder
IntelGenx Announces Initial Closing of atai Investment
Load more